Background:
Proliferation of
activated CD4+ T
lymphocytes is
inhibited by
indoleamine
2,3-dioxygenase (IDO).
Objective: We
undertook the
present study to
test the hypothesis
that IDO-expressing
immature DCs (imDCs)
can restore immune
tolerance in mice
suffering from
allergic airway
inflammation.
Methods:
imDCs were generated
from murine bone
marrow cells using
granulocyte-macrophage
colony-stimulating
factor. The imDCs
were subsequently
transfected with an
IDO expression
vector
(pEGFP-N1-IDO).
Surface marker
expression,
including CD11c, MHC
II, CD80, and CD86,
was analyzed using
flow cytometry. IDO-expressing
imDCs were injected
into the trachea of
ovalbumin
(OVA)-sensitized
mice, and lung
histopathology and
cytokine expression
in bronchoalveolar
lavage fluid were
assessed. The
splenic CD4+ T cells
of OVA-sensitized
mice were isolated
and co-cultured with
pEGFP-N1-IDOexpressing
imDCs, and apoptosis
of CD4+ T cells was
detected using the
terminal
deoxynucleotidyl
transferase dUTP
nick end labeling
assay.
Results:
Expression of IDO in
imDCs did not alter
cell surface
molecule expression.
We observed marked
lung inflammation,
elevated total cell
and eosinophil
count, and altered
cytokine levels in
OVA-sensitized mice.
These parameters
improved upon
inoculation with
IDOexpressing imDCs.
Co-culture with IDO-expressing
imDCs also induced
apoptosis, inhibited
IL-4 and IL-5
expression, and
upregulated IFN-γ
expression in CD4+ T
cells.
Conclusions:
IDO-expressing imDCs
induced TH2 cell
apoptosis and
reduced TH2 cell
activation and
allergic airway
inflammation in
OVAsensitized mice.
Thus, upregulation
of IDO expression
may provide a novel
immunointervention
strategy for asthma
treatment.
Key words:
Immune tolerance.
Indoleamine
2,3-dioxygenase.
Immature dendritic
cell.
|